Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Drug: standard therapy
- Registration Number
- NCT03395587
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
The primary objective of the study is to determine whether overall survival of newly diagnosed glioblastoma patients treated with lysate-loaded, mature dendritic cell vaccines as add-on to the standard of care consisting of resection, radiotherapy with concomitant temozolomide chemotherapy and subsequent adjuvant temozolomide chemotherapy is superior to the treatment with the standard of care alone.
- Detailed Description
This is a multicenter, randomized, phase 2 study, integrating vaccination with tumorlysate-loaded mature dendritic cells into standard radio/temozolomide-chemotherapy of newly diagnosed glioblastoma patients with near-complete resection after fluorescence-guided resection. Only patients with confirmed gross-total resection and a residual tumor volume below 5 ml will be eligible for the trial. Vaccination will be performed after radio- and concomitant temozolomide chemotherapy and during the first three cycles of adjuvant TMZ.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 136
Determined at pre-screening (prior to surgery; wk-3 - wk-1):
- Patients ≥ 18 years of age at surgery.
- Patients must be in a cognitive state to understand and sign the informed consent indicating that they are aware of the investigational nature and procedures of the study.
- First written informed consent for screening for eligibility, including tumor tissue collection, transfer and processing, central neuropathological evaluation of Tumor sample, central neuroradiological assessment of extent of resection, infectious disease (HIV, HBV, HCV, Treponema pallidum) testing, determination of MGMT promoter methylation status and pregnancy testing.
Determined at screening (at and post-surgery; d0 - wk3):
- Newly diagnosed, monofocal GBM, IDH wildtype (WHO grade IV), including the histological variants of gliosarcoma and giant cell glioblastoma, confirmed by central neuropathologist according to the WHO classification of central nervous System tumors 2016. Tumors may cross into, but not beyond the corpus callosum.
- Near-complete resection (≤ 5 ml residual contrast enhancing tumor volume) confirmed by central neuroradiologist on MRI scan within 72 h postoperative; awake surgery and second look surgery are possible, if medically indicated.
- Sterile tumor sample of ≥ 150 mg with tumor cell frequency ≥ 60% as determined by central neuropathologist available for vaccine production.
- Successful production of sterile, avital tumor lysate.
- Karnofsky performance status ≥ 70%.
- Adequate hepatic (serum glutamate pyruvate transferase/alanine transaminase (SGPT/ALT), serum glutamic oxaloacetate transaminase/aspartate transaminase (SGOT/AST) and alkaline phosphatase ≤ 3-times upper limit of normal (ULN); bilirubin ≤ 1.5-times ULN) and renal functions (creatinine ≤ 1.5-times ULN).
- Adequate bone marrow function (hemoglobin ≥ 10 g/dl, thrombocytes ≥ 100,000/μl, white blood cell count ≥ 3,000/μl; neutrophil count ≥ 1,500/μl).
- Prothrombin time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6x ULN unless therapeutically warranted. International normalized ratio (INR) (in absence of anticoagulation treatment) ≤ 1.5.
- Systemic corticosteroids tapered down to ≤ 2 mg of dexamethasone or equivalent per day within 7 days postoperative (use of corticosteroids during the treatment period should be avoided, however it is possible if clinically indicated, but may require interruption of dendritic cell vaccination).
- Female patients with reproductive potential and male generative patients and their female partners must agree to be true abstinent or to use a highly effective form of contraception (pearl index < 1%) during the trial.
- Patients must be in a cognitive state to understand and sign the informed consent indicating that they are aware of the investigational nature and procedures of the study.
- Written informed consent to participate in study.
determined at pre-screening (prior to surgery; wk-3 - wk-1):
- Medical history of severe acute or chronic disease with poor prognosis, e.g. severe coronary heart disease, heart failure (New York Heart Association classes III/IV), severe poorly controlled diabetes, severe mental retardation or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- Medical history of severe autoimmune disorder or immunodeficiency or patients with organ allograft.
- Medical history of bleeding diathesis or coagulopathy.
- Prior malignancy during the last three years except non-melanoma skin cancer, in situ cervical cancer, treated superficial bladder cancer or cured, early-stage prostate cancer in a patient with prostate-specific antigen (PSA) level less than ULN.
- Previous radiotherapy to head and neck.
- Known allergy or intolerability to TMZ, dacarbazine, the contrast agent or to components of the dendritic cell vaccine.
- Current treatment of glioblastoma in another clinical trial with therapeutic intervention or current use of any other investigational agent.
- Known pregnancy or breast feeding.
- No known severe infection requiring treatment.
- Accommodation in an institution due to legal orders (§40(4) AMG).
- Evidence of current drug or alcohol abuse. determined at screening (at and post-surgery; d0 - wk3):
- Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema pallidum or other severe infection requiring treatment.
- Accommodation in an institution due to legal orders (§40(4) AMG).
- Pregnant or breast feeding female patients. From pre-menopausal female patients with childbearing potential a negative pregnancy test must be obtained.
- Any psycho-social condition hampering compliance with the study protocol.
- MGMT promoter methylation status equivocal.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental intervention Autologous, tumor lysate-loaded, mature dendritic cells (DC) Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35) Control intervention standard therapy Standard therapy: Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
- Primary Outcome Measures
Name Time Method Overall survival (OS) Day of surgery until death of any cause assessed up to 34 months Overall survival as measured from the day of surgery until death from any cause assessed up to 34 months
- Secondary Outcome Measures
Name Time Method Quality of life of cancer patients 34 months Quality of life as determined by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 3.0
Progression free survival (PFS) Day of surgery until day of diagnosis of tumor progression assessed upto 34 months Progression-free survival as measured from the day of surgery until diagnosis of tumor progression by MRI scan according to modified Response Assessment in Neuro-Oncology (RANO) criteria assessed up to 34 months
OS rates 6, 12 and 24 months after the day of surgery OS rates at 6, 12 and 24 months after the day of surgery
PFS rates 6, 12 and 24 months after the day of surgery PFS rates at 6, 12 and 24 months after the day of surgery
Frequency and severity of adverse events 34 months Safety based on the frequency and severity of adverse events (AE) with toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 4.03 (CTCAE 4.03)
Karnofsky Performance Status 34 months Overall and neurological performance based on the Karnofsky performance status (MMSE-2)
MMSE-2 34 months Overall and neurological performance based on the Minimal Mental State Examination 2 (MMSE-2)
Psychological distress in oncology patients 34 months Quality of life as determined by the Distress Thermometer (DT)
Quality of life in patients with brain cancer 34 months Quality of life as determined by the European Organization for Research and Treatment of Cancer (EORTC) Brain Cancer Module QLQ-BN20
Psychological distress, anxiety and depression 34months Quality of life as determined by the Hospital Anxiety and Depression Scale (HADS) for psycho-oncological strain assessment
Trial Locations
- Locations (6)
Klinik für Neurochirurgie, Sana Kliniken Duisburg
🇩🇪Duisburg, Northrhine Westphalia, Germany
Klinik für Neurologie, Knappschaftskrankenhaus Bochum
🇩🇪Bochum, Northrhine Westphalia, Germany
Neurochirurgische Klinik, Universitätsklinikum Düsseldorf
🇩🇪Düsseldorf, Northrhine Westphalia, Germany
Klinik für Allgemeine Neurologie, Universitätsklinikum Münster
🇩🇪Münster, Northrhine Westphalia, Germany
St. Marien Hospital Lünen, Klinik für Neurochirurgie
🇩🇪Lünen, NRW, Germany
Helios Klinikum Krefeld, Klinik für Neurochirurgie
🇩🇪Krefeld, Germany